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Background: Neurofibromatosis type-1 (NF1) is a complex neurogenetic disorder characterised by the development
of benign and malignant tumours of the peripheral nerve sheath (MPNSTs). Whilst biallelic NF1 gene inactivation
contributes to benign tumour formation, additional cellular changes in gene structure and/or expression are
required to induce malignant transformation. Although few molecular profiling studies have been performed on
the process of progression of pre-existing plexiform neurofibromas to MPNSTs, the integrated analysis of copy
number alterations (CNAs) and gene expression is likely to be key to understanding the molecular mechanisms
underlying NF1-MPNST tumorigenesis. In a pilot study, we employed this approach to identify genes differentially
expressed between benign and malignant NF1 tumours.
Results: SPP1 (osteopontin) was the most differentially expressed gene (85-fold increase in expression), compared
to benign plexiform neurofibromas. Short hairpin RNA (shRNA) knockdown of SPP1 in NF1-MPNST cells reduced
tumour spheroid size, wound healing and invasion in four different MPNST cell lines. Seventy-six genes were found
to exhibit concordance between CNA and gene expression level.
Conclusions: Pathway analysis of these genes suggested that glutathione metabolism and Wnt signalling may be
specifically involved in NF1-MPNST development. SPP1 is associated with malignant transformation in NF1-associated
MPNSTs and could prove to be an important target for therapeutic intervention.
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Neurofibromatosis type 1 (NF1) (MIM# 162200), a com-
plex autosomal dominant disorder with a highly varia-
ble clinical phenotype, affects approximately 1 in 4,000
people worldwide (Huson, 2008). Malignant complications
are relatively rare manifestations of this disorder but in-
clude brain tumours, optic gliomas and malignant per-
ipheral nerve sheath tumours (MPNSTs) [1,2]. MPNSTs
can either occur sporadically or instead may develop
from the malignant transformation of pre-existing NF1-
associated plexiform neurofibromas (PNF) or from a focal* Correspondence: upadhyaya@cardiff.ac.uk
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unless otherwise stated.subcutaneous neurofibroma. The lifetime risk of develop-
ing MPNSTs in NF1 patients is 10%–15% [3,4].
MPNSTs are a significant cause of morbidity and mor-
tality in NF1. Upon first presentation, MPNSTs are often
non-resectable because the tumour is already at a late
stage of development; metastases may also be present,
most commonly in the lung but also in the liver and
brain. Consequently, the 5-year survival rate for indivi-
duals with these tumours is only 20%–50%, and the 10-
year survival rate is even lower (7.5%) [5]. Currently,
there are no effective treatments for MPNSTs; although
complete surgical excision with clear margins is the ther-
apy of choice, chemotherapy has sometimes also been
employed despite its limited effectiveness. Several risk
factors confer an increased likelihood of MPNST develop-
ment, e.g. multiple internal PNFs [6], previous radiationl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Venn diagram comparison based upon the less
stringent and stringent gene list. a. Venn diagram based upon
the less stringent gene lists from the 4 vs. 5 and 3 vs. 3 pairwise
comparisons. b. Venn diagram based upon the stringent gene lists
from the 4 vs. 5 and 3 vs. 3 pairwise comparisons.
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tion that removes the entire NF1 gene [7], the presence of
neurofibromatous neuropathy [8] or a family history of
NF1-MPNSTs [9]. Since there are no reliable predictive or
prognostic biomarkers for MPNSTs, the progression of a
pre-existing plexiform neurofibroma to an MPNST cannot
currently be predicted in advance on the basis of molecu-
lar (copy number and/or gene expression) profiling des-
pite recent significant advances in this field. Beert et al.
(2011) demonstrated recurrent homozygous loss of the
CDKN2A locus in 15/16 atypical neurofibromas; this find-
ing supports the notion that atypical neurofibromas con-
stitute intermediates between benign neurofibroma and
MPNSTs and further suggests that CDKN2A loss is an
early step in the progression of neurofibroma to MPNSTs
[10]. A detailed knowledge of the NF1 somatic mutational
spectrum of MPNSTs is, however, a prerequisite for the
development of targeted therapies. Although somatic in-
activation of the wild-type NF1 allele is presumed to be
the key step in NF1-associated tumour development, this
cannot on its own explain the malignant transformation
of benign plexiform neurofibromas to MPNSTs. This indi-
cates that additional genetic (and potentially epigenetic)
alterations are required to bring about malignancy.
High-throughput whole genome microarray profiling
has proved to be one of the most effective methods to
analyse large numbers of clinical samples across multiple
tumour types. Indeed, a considerable number of studies
have identified somatic copy number alterations (CNA)
and concomitant gene expression changes in benign and
malignant NF1-associated tumours [11-30]. However,
despite the plethora of previous array-based investiga-
tions, relatively few genes have so far been identified that
are consistently mutated across multiple MPNSTs. Such
frequently mutated genes may harbour ‘driver mutations’
(as opposed to ‘passenger mutations’) that promote NF1
malignant transformation. MPNST development is clearly
a complex multistep process in which the mutation of a
large number of genes, contributing to the deregulation of
multiple signalling and regulatory pathways, is to be ex-
pected. Whole genome analysis and, in particular, the fo-
cussed investigation of specific pathways are likely to be
key to determining the underlying molecular mechanisms
involved in MPNST tumorigenesis. Genes that could be
informative in a prognostic context may be identified
through the use of integrated CNA/gene expression
analysis performed on the same sample sets [31,32]. To
this end, the present study employed Affymetrix Human
Exon 1.0 ST Arrays to screen both PNF and MPNST
tumour DNAs from nine unrelated NF1 patients to gener-
ate data on differences in gene expression at the whole
genome level between benign and malignant tumours
with which to compare with previously generated CNA
data derived from the same tumours in order to disclosenovel genes and pathways that could be important in
MPNST development [25].
Results
Identification of differentially expressed genes between
neurofibromas and MPNSTs
For differential expression analysis, different sets of genes
were identified from the various analyses (Figure 1a,b) that
we performed: (1) 4 benign tumour samples vs. 5 malig-
nant tumour samples with stringent criteria applied, (2) 4
benign tumour samples vs. 5 malignant tumour samples
under less stringent criteria, (3) 3 benign tumour samples
vs. 3 malignant tumour samples under stringent criteria
and (4) 3 benign tumour samples vs. 3 malignant tu-
mour samples under less stringent criteria (Additional
file 1: Table S2). The genes identified employing the less
stringent criteria from the 4 vs. 5 analyses were cross-
compared with the corresponding list of genes identified
by means of the 3 vs. 3 analysis (Figure 1a). The same
process was then followed for those genes identified using
the more stringent criteria (Figure 1b). Given the relatively
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ence of outliers (patients exhibiting variable expression
compared with the median) was expected to have a con-
siderable influence on the combined results. With this in
mind, the analysis as described above was performed with
and without those outlier/variable samples.
The number of genes identified as being differentially
expressed between benign and malignant tumours under
more or less stringent criteria in the 3 vs. 3 and 4 vs. 5
analyses can be found in Table 1. Under the less stringent
criteria, statistical testing employed a P value threshold of
0.05, which served to identify genes displaying ≥1.3-fold
(absolute) differential gene expression. In the differential
analysis, which considered all profiled samples (4 benign
vs. 5 malignant), a total of 1,957 genes were identified as
being differentially expressed between benign and malig-
nant tumours whereas in the differential analysis which
excluded the three samples at the expression range ex-
tremes (3 benign vs. 3 malignant), only 1,259 genes were
identified. The two different conditions of stringency were
used for the sake of comparison. However, for the final
analysis, the genes identified under the more stringent cri-
teria were used. Under the more stringent criteria, statis-
tical testing employed a P value threshold of 0.005, which
was deemed to be sufficient to identify genes displaying
1.5-fold or more (absolute) differential gene expression. In
the 4 vs. 5 stringent gene list analysis, 258 genes were
identified as being differentially expressed between benign
and malignant tumours whereas in the 3 vs. 3 analyses,
the number of genes identified was 127. The top 20 sig-
nificantly differentially expressed genes identified using
the more stringent criteria are given in Table 2.
The SPP1 gene [NCBI: NM_001040058] (osteopontin;
OPN) was found to exhibit the most significantly elevated
differential mean expression level between the benign and
malignant tumours. SPP1 was therefore selected for fur-
ther functional analysis to assess its possible role in malig-
nant transformation. Exon array analysis identified a mean
expression level of 12.06 (log2) for SPP1 in malignant tu-
mours and a mean expression level of 5.65 (log2) in be-
nign plexiform neurofibromas. This equates to an 85-fold
increase (based on anti-logged LS means) in expression inTable 1 Definitions of stringent and less stringent
analytical criteria and the numbers of genes detected by
the 3 vs. 3 and 4 vs. 5 analyses under both sets of criteria
Less stringent criteria Stringent criteria
Statistical testing P value 0.05 0.005
Fold change 1.3 1.5
Number of genes 4 vs. 5 1,957 258
Number of genes 3 vs. 3 1,259 127
Definition of stringent and less stringent analytical criteria and the numbers of
genes detected by the t vs. 3 and 4 vs. 5 analyses under both sets of criteria.MPNSTs compared to benign plexiform neurofibromas
(P = 0.0002) (Table 2). Since this was the highest fold
change in expression observed between benign and ma-
lignant tumours for all the genes identified in this ana-
lysis, an association with malignant transformation was
strongly suspected. Significant reductions in the expres-
sion of ADH1B and GRIK2 (P values 0.0003 and 0.0004,
respectively) in MPNSTs as compared to benign plexiform
neurofibromas were however also observed (Table 2).
Quantitative real-time PCR (q-PCR)
Gene expression changes initially detected by Affymetrix
Human Exon 1.0 ST Array analysis were validated by
q-PCR. We aimed to determine where there was a cor-
relation between the presence of a copy number alteration
and gene expression (either a concomitant increase in
copy number and gene expression or a decrease in both)
as assessed by quantitative PCR. This was determined by
identifying whether the same directional change as noted
above was identified in the array data from the current
study and CNA data from the previous analyses [25]
(Additional file 2: Table S3). A correlation was noted
for 11 of the 20 differentially expressed genes analysed
(Additional file 3: Figure S1) (ADH1B, FAP, FLJ42200,
GRIK2, GTDC1, KIAA0746, KRTAP13-4, PEG3, NSBP1,
PTGIS and SPP1). For six of the genes (CCT5, CD72,
COL10A1, FAM177A1, SLC25A12 and TDP1), we were
unable to identify a correlation (i.e. concordance) bet-
ween the copy number alteration and gene expression
in six of the tumour samples tested. For the remaining
three genes (CSRP1, GRIK3 and EFHC2), half the sam-
ples yielded findings compatible with, and anticipated
from, the results of the exon array experiments; the
remaining samples either demonstrated no change in
gene expression or the opposite change to that antici-
pated on the basis of the exon array results (i.e. a de-
crease in gene expression identified by array, increase
in gene expression identified by Q-PCR) (see Additional
file 3: Figure S1).
Integration of copy number analysis with differentially
expressed genes
CNA data were derived from a previously published ana-
lysis of the same tumours [25]. In total, 27 genes were
common to HMM and expression analysis, whereas 120
genes were common to segmentation and expression
analysis. We then selected those genes that were com-
mon to expression analysis and HMM and/or segmenta-
tion analysis (121 genes in total; see Figure 2). Of these
121 genes, gene expression and CNA data were con-
cordant in 76 (63%) cases, with all 76 genes displaying
the same directional change of both CNA and gene ex-
pression (Additional file 2: Table S3). The 76 genes that
were concordant for copy number and gene expression
Table 2 The top 20 genes identified as being significantly differentially expressed between MPNSTs and PNFs in the
more stringent analysis of 3 vs. 3 samples




Fold change P value Chromosome Start Stop




2584134 FAP NM_004460 4.87 8.75 14.75 0.0001 2 163027200 163101589
4013828 NSBP1 NM_030763 5.22 3.67 −2.92 0.0001 X 80211860 80457431
3917555 KRTAP13n4 NM_181600 3.77 3.13 −1.55 0.0001 21 31797943 31809269
3908934 PTGIS NM_000961 4.58 6.60 4.06 0.0002 20 48120414 48185550
2764192 KIAA0746 NM_015187 4.33 5.82 2.80 0.0002 4 25722248 25865344
2735027 SPP1 NM_001040058 5.65 12.06 85.19 0.0002 4 88408243 88904561
3532353 FAM177A1 NM_001079519 8.01 7.11 −1.86 0.0003 14 35508201 35582327
2779231 ADH1B NM_000668 6.50 3.18 −9.99 0.0003 4 100226131 100242895
2406926 GRIK3 NM_000831 7.20 3.85 −10.19 0.0004 1 37266614 37524753
3916290 FLJ42200 AK124194 3.32 4.05 1.65 0.0004 21 25353415 25920256
2970942 COL10A1 NM_000493 3.56 4.67 2.17 0.0004 6 116440092 116518549
2450865 CSRP1 NM_004078 9.09 7.28 −3.50 0.0005 1 201445919 201481500
2918982 GRIK2 NM_175768 7.02 3.47 −11.66 0.0005 6 101841683 102690448
3204648 CD72 NM_001782 4.08 5.08 1.99 0.0005 9 35609970 35646790
4006326 EFHC2 NM_025184 4.84 3.42 −2.67 0.0005 X 44006888 44309044
2586845 SLC25A12 NM_003705 5.56 6.30 1.68 0.0006 2 172639117 172750960
2579439 GTDC1 NM_001006636 6.95 5.92 −2.05 0.0006 2 144702190 145123135
3872053 PEG3 NM_006210 5.58 4.17 −2.65 0.0006 19 57285930 57352082
2801526 CCT5 NM_012073 8.62 9.33 1.64 0.0006 5 10250111 10266501
3548152 TDP1 NM_018319 4.17 5.49 2.50 0.0007 14 90421293 90511103
The top 20 genes identified as being significantly differentially expressed between MPNSTs and PNFs in the more stringent analysis of 3 vs. 3 samples.
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ment in malignancy (Additional file 2: Table S3).
Pathway analysis
The 76 concordant genes, which were common to both
the CNA and expression analyses, were interrogated
using all pathways in the METACORE database. Path-
ways in which more than one gene was subject to con-
comitant alterations in both copy number and expression
were then listed. The top ten pathways (by P value) are
given in Table 3. These pathways include the glutathione
metabolism, Wnt signalling, cell adhesion and alpha-6/
beta 4 integrin pathways.
SPP1 knockdown in multiple MPNST cell lines impairs
tumour formation, wound healing and invasion
Given that we observed significant differences in the ex-
pression level of SPP1 in MPNSTs as compared with the
benign plexiform neurofibromas and the fact that SPP1
plays significant roles in both tumorigenesis and metas-
tasis [33], we knocked down expression of the SPP1 gene
in four MPNST cell lines (ST8814, S462, S1844.1 andS1507.2) and examined both the ability of these cell lines
to form tumours (Figure 3a) and the effect of knock-
down on wound healing and invasion. Both control and
SPP1 knockdown cell lines formed tumour colonies in
soft agar. However, SPP1 knockdown caused a signifi-
cant reduction in tumour spheroid size (n = 40, P =
0.0001) in all MPNST cell lines tested (Figure 3b). We
next analysed the effects of SPP1 knockdown on cell mi-
gration during wound healing (Figure 4a). In all cell
lines, knockdown of SPP1 robustly inhibited wound
closure (Figure 4b) (P values for the ST8814, S462,
S1844.1 and S1507.2 cell line were 0.03, 0.001, 0.001 and
0.003, respectively), suggesting a possible role for SPP1
in metastasis. This role was further supported by the
results of cellular invasion assays, which revealed that
SPP1 knockdown significantly reduces the cells’ invasive
properties (P values for the ST8814, S462, S1844.1 and
S1507.2 cell line were 0.0001, 0.001, 0.0001 and 0.001,
respectively) (Figure 4b,c). Validation of specific gene
knockdown using short hairpin RNA (shRNA) clones
was completed by Western blot analysis. A β-actin con-
trol blot was performed to confirm that there were no
Figure 2 Venn diagram comparing the numbers of genes from
the HMM and segmentation copy number analyses with the
genes found to be differentially expressed.
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knockdown with shRNA resulted in a significant reduc-
tion in both wound healing and invasiveness.
Discussion
The functional loss of neurofibromin, due to NF1 gene
inactivation, leads to increased cell growth and prolifera-
tion through constitutive Ras pathway signalling. Although
this is necessary for benign neurofibroma formation, it is
insufficient to explain the malignant transformation of a
benign PNF to an MPNST, since additional genetic lesions
(and/or epigenetic modifications) are required for this to
occur [25].
Initially, this study aimed to identify genes that con-
tribute to the malignant transformation of benign neuro-
fibromas by establishing which genes were differentially
expressed between benign and malignant tumours in
NF1 patients. A previously compiled list of genes located
within regions encompassed by copy number alterations
(CNAs) identified in the NF1-MPNSTs which were also
used in the current study [25] was then cross-compared
with a list of genes differentially expressed in the same
NF1-MPNST samples, which were analysed for this
study through Affymetrix exon array analysis. Finally,
an additional study involving pathway analysis was per-
formed on those genes that were common to the re-
sults of the CNA and exon array analyses.In previous studies of NF1-MPNSTs, many genetic al-
terations, including copy number alterations and dif-
ferential gene expression, have been identified but no
specific molecular signature pathognomonic of malig-
nant transformation has so far been defined [11-30].
Identifying genes that are differentially expressed be-
tween benign and malignant tumours not only promises
to improve our understanding of the process of malig-
nant transformation but should also aid in identifying
potential therapeutic targets.
This study employed the GeneChip Human Gene 1.0
ST array (Affymetrix, Santa Clara, USA). This array is a
whole transcript-based array for gene expression pro-
filing which, unlike older Affymetrix arrays, queries the
entire transcript instead of just the 3′ end [34]. Additio-
nally, this array uses a labelling protocol that generates
biotinylated sense strand DNA instead of complemen-
tary RNA (cRNA), thereby yielding DNA-DNA duplexes,
which are more specific than the RNA-DNA duplexes
generated using standard protocols [35]. This array pro-
vides approximately 25-mer probes designed to be dis-
tributed across the transcribed regions of each gene with
a median of 26 probes per gene, giving two complemen-
tary levels of expression analysis in a single experiment,
both “exon-level” and “gene-level” analysis. The array in-
terrogates 28,869 well-annotated genes with 764,885 dis-
tinct probes. The array is based on the March 2006
(UCSChg18, NCBI Build 36) human genome sequence
assembly. The Affymetrix Human Exon 1.0 ST array con-
tains 17,881 transcripts. Whole genome Affymetrix exon
arrays have been employed in a number of different stud-
ies of cancer including non-small cell lung, colon, bladder
and prostate cancer [36,37].
The comparative transcriptome analysis reported here
identified the SPP1 gene to be the single most differen-
tially overexpressed gene in NF1-MPNSTs as compared
to benign tumours. SPP1 was selected for further study
not only for this reason but also because of its well-
documented involvement in cell signalling, tumorigen-
esis and metastasis [38-49]. shRNA knockdown of four
different MPNST cell lines revealed a significant reduc-
tion in tumour colony size growth, wound healing and
cell invasion, thereby supporting a role for the increased
expression of SPP1 in the malignant transformation and
invasion of cells during NF1-MPNST development. SPP1
is an extracellular matrix protein with cytokine properties.
It is involved in extracellular matrix (ECM) and adhesion-
related pathways where it performs key roles in cell-cell
communication, focal adhesion, immune cell activation
and immune cell migration. It plays an essential role in
the pathway that leads to type I immunity, thereby enhan-
cing the production of interferon-gamma and interleukin-
12 and reducing interleukin-1 synthesis. In terms of
an association with cancer, SPP1 has been shown to
Table 3 Pathway Enrichment analysis
Pathway name P value Genes Fold change (3 benign
vs. 3 malignant)
Fold change (4 benign
vs. 5 malignant
1 Glutathione metabolism 0.00056 GSTM1 −3.25 −2.27
GSTM2 −3.25 −2.27
GSTM4 −3.25 −2.27
2 Glutathione metabolism/human version 0.00059 GSTM1 −3.25 −2.27
GSTM2 −3.25 −2.27
GSTM4 −3.25 −2.27
3 Glutathione metabolism/rodent version 0.00073 GSTM1 −3.25 −2.27
GSTM2 −3.25 −2.27
GSTM4 −3.25 −2.27
4 Development: Wnt signalling pathway. Degradation of
beta-catenin in the absence Wnt signalling
0.00106 CSNK1D 2.42 1.99
DAB2 3.46 2.65
5 Cell adhesion: PLAU signalling 0.00445 HGF 7.80 10.97
SERPINE1 5.74 4.54
6 Role of alpha-6/beta-4 integrins in carcinoma progression 0.00589 HGF 7.80 10.97
LIMK1 2.04 2.23
7 Development: TGF-beta-dependent induction of EMT via MAPK 0.00641 DAB2 3.46 2.65
SERPINE1 5.74 4.54
8 Transport: macropinocytosis regulation by growth factors 0.01130 HGF 7.80 10.97
LIMK1 2.04 2.23
9 Development: regulation of epithelial-to-mesenchymal
transition (EMT)
0.01165 HGF 7.80 10.97
SERPINE1 5.74 4.54
10 Transport: clathrin-coated vesicle cycle 0.01421 PREB 1.45 1.43
DAB2 3.46 2.65
The pathways were ranked by hypergeometric P values, and a summary of the top ten pathways is reported. The P value represents the probability that a gene
set of this size would co-occur by chance alone. Network objects represent the ratio of the number of genes from the list compared to the total number of genes
known to be associated with the pathway.
a
b
Figure 3 SPP1 knockdown reduces tumour size in soft agar. Stable ST8814, S462, S1844.1 and S1507.2 cell lines, expressing either non-target
or SPP1 shRNA as indicated, were subjected to tumour spheroid growth assays. a) Photographs of 40 tumours were taken after 2 weeks of
incubation. The diameter of all tumours was measured using ImageJ software; the scale bar on images represents 250 μm. b) The percentage of
tumour size was calculated from the 40 tumours for both the control and SPP1 shRNA. SPP1 knockdown significantly reduced tumour size in all
four MPNST cell lines, consistent with a role for SPP1 in tumour growth (P = 0.0001), *P < 0.05 when comparing treated vs. untreated cells.
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Figure 4 SPP1 knockdown impairs wound healing and cell invasion. Stable ST8814, S462, S1844.1 and S1507.2 cell lines, expressing either
non-target or SPP1 shRNA, as indicated, were subjected to a wound healing assay. a) Pictures of cells were taken at 0 and 18 h after wounding.
b) The percentage of cell migration was calculated using three individual experiments. SPP1 knockdown significantly reduced cell migration
during wound healing in all four MPNST cell lines [P values for the four cell lines were as follows: ST8814 (0.03), S462 (0.001), S1844.1 (0.001),
S1507.2 (0.003)]. c) SPP1 knockdown significantly reduced cell invasiveness; crystal violet was used to stain invasive cells. Cells were then eluted
with 1% (w/v) SDS, and the absorbance was read at 550 nm on a Genova MK3 Lifescience Analyser; the number of cells was calculated by
plotting the absorbance against a standard curve. The percentage of invasive cells was calculated in three individual experiments. SPP1 knockdown
significantly reduced cell invasion in all four MPNST cell lines, suggesting a potential role for SPP1 in metastasis [P values for the four cell lines were as
follows: ST8814 (0.0001), S462 (0.001), S1844.1 (0.0001), S1507.2 (0.001). *P < 0.05 when comparing treated vs. untreated cells].
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harbouring activated RAS have been found to exhibit a
higher level of SPP1 [50]. It could therefore be that the
activation of RAS through the functional loss of neurofi-
bromin (due to NF1 gene inactivation) gives rise to theoverexpression of SPP1. Furthermore, the use of SPP1 in-
hibitors such as agelastatin A has successfully reduced col-
ony formation, migration and invasion in human breast
cancer cell lines [51]. Whilst SPP1 has the highest level of
differential gene expression, the remaining genes in Table 2
Figure 5 To confirm efficient knockdown, SPP1 protein levels were compared between control and SPP1 knockdown cell lines by
Western blot. β-actin was used as a loading control. SPP1 protein levels were significantly reduced after SPP1 knockdown in all MPNST cell lines.
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would help to explore further the relationship with NF1 of
not only SPP1 but the other identified statistically signifi-
cant genes, which are differentially expressed between be-
nign and malignant NF1 tumours.
In an attempt to explore the relationship between gene
expression and copy number variation in the context of
NF1 tumorigenesis, we attempted to integrate previous
copy number data derived from the MPNSTs under
study here [25], with the newly generated data on differ-
entially expressed genes. The same tumour samples were
utilised for both analyses. The identification of prognos-
tic biomarkers for NF1-MPNSTs using gene expression
microarrays is challenging in that there are very few can-
didate genes in common between the different studies
so far performed [11-30]. However, over the last 5 years,
studies of cancer have begun to integrate gene expres-
sion and copy number analysis in an attempt to explore
underlying mechanisms of tumorigenesis and to identify
potential gene and pathway biomarkers [31,32]. Such an
integrative approach has led to advances in our under-
standing of the role of copy number alterations in tu-
morigenesis. Thus, for example, the Cancer Genome
Atlas project [52] is generating multiple datasets using
different platforms (e.g. gene expression and copy num-
ber analysis) from the same set of patients. Although the
increased expression of a particular gene does not by it-
self constitute direct evidence for the role of that gene
in tumorigenesis, concomitant copy number alterations
may serve to disrupt metabolic and physiological pro-
cesses, thereby contributing indirectly to tumorigenesis
[31,32]. There is however compelling evidence for a cis-
dosage effect of CNA on gene expression [53], and this
relationship can facilitate the identification of novel
genes involved in tumorigenesis as well as other aspects
of cancer biology. In any such analysis, it is important to
be aware of cellular heterogeneity within the tumour [54].
Work on different tumours, including breast, lung,
prostate, hepatocellular carcinoma and melanoma, has
yielded an estimate of the proportion of all differentially
expressed genes whose expression is concordant with
their copy number status. This has been shown to vary
between 32% and 78% [31,32,55,56]. In this context, it
is encouraging that in the current study, 63% of genes
were found to be concordant in terms of their expres-
sion and copy number status. However, although SPP1was found to be the most differentially expressed gene
in the initial part of this study, we failed to find any
copy number changes in MPNSTs in our earlier study
and thus its expression was not concordant with the
copy number changes [25]. For this reason, we propose
that the observed upregulation of SPP1 gene expression
may not have been modulated by a copy number alter-
ation. This is especially in view of the fact that no copy
number alterations involving SPP1 have previously been
reported in a variety of cancers and tissue types (by ref-
erence to COSMIC and CONAN) [57,58], including
NF1 MPNSTs [40]. Thus, in the absence of gene dupli-
cation/amplification/deletion, it may be that there are
other genetic mechanisms including DNA methylation,
point mutations, up- or downregulated transcription
factors, regulation of messenger RNA (mRNA) tran-
scription or microRNAs (miRNAs) [59-61] that could
influence the expression of the non-concordant genes
(37%) identified in this study.
Finally, we performed pathway analysis on the 76
genes that were common to the copy number array and
exon array data. Integration of clinical information with
copy number and gene expression data has led to the
identification of genes common to CNA regions and ex-
pression array datasets that are consistently associated
with clinical outcomes including lung cancer, thereby
underlining the clinical relevance and utility of such data
sets [56]. The top ten statistically significant pathways
were noted from those where two or more genes ex-
hibiting alterations in copy number and/or expression
belonged to the same pathway (Table 3). These path-
ways included glutathione metabolism, Wnt signalling,
cell adhesion PLAU and intracellular signalling by alpha-
6/beta-4 (a6b4) integrins. The Wnt signalling pathway, in-
cluding the genes CSNK1D and DAB2 in this data set
(Table 3), is of particular interest. The APC gene belongs
to the Wnt pathway and is somatically mutated in various
cancers and also in familial adenomatous polyposis, which
results from inherited APC gene mutations [62]. In hu-
man colon cancer, SPP1 is a transcriptional target of aber-
rant Wnt signalling, and SPP1 expression alone predicts
survival [63]. Vinas et al. (2010) demonstrated that the
antiapoptotic role of Wnt was mediated by SPP1, a direct
Wnt target gene, and SPP1 was reduced by Wnt antibody
administration in vivo [64]. Using comparative transcrip-
tome analysis, Mo et al. (2013) previously demonstrated
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motion of MPNST growth [26]. Furthermore, using a
sleeping beauty forward genetic screen, the Wnt pathway
has been found to be a driver of MPNST development
[27]. Most interestingly, in a recent study, 20 Wnt genes
exhibited altered expression in MPNST biopsies and cell
lines in comparison to benign neurofibromas [30]. Taken
together, it has become clear that progression to malig-
nancy requires many genomic alterations acting in con-
cert. Importantly, our results appear to concur with the
findings of previous studies that the canonical Wnt signal-
ling pathway is likely to be a key driver of MPNST devel-
opment. Thus, members of the Wnt pathway may not
only constitute potential biomarkers of MPNST tumori-
genesis but also represent potential therapeutic targets for
small molecule inhibitors [26-28].
In addition to the Wnt signalling pathway, other path-
ways in Table 3 are also thought to be involved in cancer
progression. Specifically, although there is no clear asso-
ciation reported with NF1, altered glutathione (GSH)
metabolism is thought to be a major mechanism of che-
moresistance and GSH levels are reportedly elevated in
non-small cell lung cancer [65]. In addition, genetic vari-
ations in genes involved in the glutathione and DNA re-
pair pathways are associated with non-small cell lung
cancer survival [66]. Further analysis of the pathways in
Table 3 would be important to ascertain the role of the
NF1 gene in other cancers.
Conclusions
Although MPNSTs only develop in approximately 15%
of NF1 patients, they represent a frequent cause of lethal
progression of the NF1 phenotype. It is clear that many
genetic (and potentially epigenetic) factors contribute to
abnormal tumour progression in these neoplasms [67,68].
The prognosis for individuals diagnosed with an MPNST
is usually very poor, especially as treatment options for
MPNSTs are currently very limited and complete surgical
excision with clear margins has proved to be very difficult.
In knockdown experiments involving shRNA for SPP1, we
found that cell migration was reduced in four different
MPNST cell lines. This exploratory study supports the
idea of a direct role for SPP1 in MPNST development and
metastasis. Although obtaining MPNST samples can be
challenging, this preliminary study warrants confirmation
in a larger panel of samples as the study has a limitation
in that it is based on a small cohort of samples. In addition
to the well-studied role of osteopontin in other cancers
[38-49], the expression of SPP1 is regulated by Wnt sig-
nalling, one of the pathways that we identified as playing a
role in the progression of benign plexiform neurofibromas
to MPNSTs [69]. This is most encouraging in terms of the
potential for those genes and pathways newly identified in
this study to help in understanding the molecular basis oftumorigenesis and malignant transformation in NF1 as
well as providing targets for therapeutic intervention in
NF1-MPNST development.
Methods
Patient samples and RNA preparation
DNA and RNA were isolated from the same segment of
tumour. RNA was extracted from nine NF1-associated
tumours with biallelic NF1 gene mutations (comprising
four benign PNFs and five high grade MPNSTs) from
nine unrelated NF1 patients using the TRIZOL method
(Invitrogen) as previously described [25]. The same tu-
mour samples were utilised in the current study and the
previous analyses for microarray analysis [25] to enable
analysis of paired CNA and gene expression data. All
total RNA samples were assessed for purity and integrity
by means of an Agilent Bioanalyser. Samples were re-
named and randomised in order to avoid order bias or
batching effects. Analysis of gene expression by Affymetrix
Human Exon 1.0 ST Array was performed by Almac
Diagnostics (Craigavon, UK). The Affymetrix Human
Exon 1.0 ST array contains 17,881 transcripts. Standard
operating protocols, as provided by the manufacturer,
were used to PCR amplify and hybridise nine NF1-
associated tumour-derived cDNA samples on Affymetrix
Human Exon 1.0 ST arrays.
Ethics statement
All patients provided informed consent and the study
was approved by the Research Ethics Committee (REC)
for Wales and appropriate institutional review boards.
Identification of differentially expressed genes between
benign neurofibromas and MPNSTs
A quality control (QC) assessment of the Exon array
profiles was performed to examine standard Affymetrix
quality parameters, expression distribution patterns and
array profile relationships. Overall, a high quality level
was achieved (median percent present = 65.99%), al-
though the average expression level of all probe sets across
the array profiles was quite variable. “percent present” rep-
resents the proportion of probe sets ‘present’ or detected
as defined by the DABG (detection above background) al-
gorithm. The DABG algorithm yields a detection metric
(P value) generated by comparing perfect match probes to
a distribution of background probes. A probe set was con-
sidered to be ‘present’ if the DABG P value was ≤0.01.
Further information is available at www.affymetrix.com.
In an attempt to mitigate the variable expression profile
observed, differential gene expression analysis was per-
formed with and without those samples from either end
of the observed expression range, namely S0342F0011
(malignant), S0342F0020 (malignant) and S0342F0030
(benign). The results that were common to both differential
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data were analysed using the robust multi-array average
(RMA) method to generate gene-level measurements [70].
The expression levels of all genes on the array were
compared between benign PNFs and MPNSTs, at two
different levels of stringency. Under the less stringent
criteria, statistical testing employed a P value threshold
of 0.05, which served to identify genes displaying 1.3-
fold or more (absolute) differential gene expression. The
two levels of stringency that were used as fold change
cut-offs, in this sense, were essentially arbitrary but ne-
vertheless provide an element of choice in terms of prio-
ritising targets to follow up. We have filtered at 1.3,
which may be interpreted as “low stringency”. However,
combined with a significant P value, this can often be
valid in the context of those biological systems where
some changes are expected to be subtle yet functionally
relevant. Moreover, although the fold change estimations
from microarray data compared to qPCR are frequently
underestimated, it is often possible to validate findings
by qPCR from the lower fold change space of microarray
data. Under high stringency criteria, statistical testing
employed a P value threshold of 0.005, which was deemed
to be sufficient to identify genes displaying 1.5-fold or more
(absolute) differential gene expression. This approach al-
lowed us to interrogate two different sets of expression
data, thereby minimising the loss of important information.
Quantitative real-time PCR (q-PCR)
All of the top 20 differentially expressed genes were inde-
pendently assessed by quantitative PCR using RNA isolated
from additional MPNST samples, not used in the previous
or current study. Due to the small initial sample size, we
felt that it was necessary to determine the validity of the
top 20 genes in an independent cohort of samples. These
20 genes, plus the B2M [NCBI: NM_004048] endogenous
control identified in our analysis were: FAP [NCBI: NM_
004460], NSBP1 [NCBI: NM_030763], KRTAP13-4 [NCBI:
NM_181600], PTGIS [NCBI: NM_000961], KIAA0746
[NCBI: NM_015187], SPP1 [NCBI: NM_001040058],
FAM177A1 [NCBI: NM_001079519], ADH1B [NCBI:
NM_000668], GRIK3 [NCBI: NM_000831], FLJ42200
[NCBI: AK124194], COL10A1 [NCBI: NM_000493],
CSRP1 [NCBI: NM_004078], GRIK2 [NCBI: NM_175768],
CD72 [NCBI: NM_001782], EFHC2 [NCBI: NM_025184],
SLC25A12 [NCBI: NM_003705], GTDC1 [NCBI: NM_
001006636], PEG3 [NCBI: NM_006210], CCT5 [NCBI:
NM_012073] and TDP1 [NCBI: NM_018319]. qPCR was
performed as previously described [25]. Primers for all
genes are listed in Additional file 4: Table S1.
Cell lines and maintenance
ST8814 MPNST-derived cell lines were purchased from
ATCC (distributed by LGC Standards, Middlesex, UK).The S462, S1507.2 and S1488.1 MPNST cell lines were a
kind gift from Prof. Mautner (University of Hamburg,
Germany) and the late Prof. Guha (University of Toronto,
Canada). After SPP1 knockdown, cell lines were cultured
and maintained in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% (v/v) foetal bovine
serum (FBS) and 1% (v/v) penicillin-streptomycin and
5 ng/ml puromycin in a humidified incubator (5% CO2
at 37°C).
Lentivirus generation and shRNA knockdown of SPP1
Both SPP1 shRNA (Clone ID: NM_000582.2-597s1c1)
and non-target control MISSION shRNA (Clone ID:
SHCO16) in pLKO.1 vector (Sigma-Aldrich Company
Ltd., Dorset, UK) were packaged into lentivirus using
HEK293T cells co-transfected (lipofectamine 2000, Life
Technology, Paisley, UK) with pLP1, pLP2 and pLP
(VSVG). Confluent MPNST cell lines were infected with
shRNA-containing lentivirus (SPP1 or non-target con-
trol) and selected over 2 weeks with 5 μg/ml puromycin
(Life Technology, Paisley, UK). Puromycin-selected mixed
cell populations were then used for tumour formation,
wound healing and invasion assays.
Tumour spheroid assays
Two-layered soft agar assays were carried out in six-well
plates. MPNST cell lines were plated in complete DMEM
media in 0.3% (v/v) agar at a density of 3 × 105cells/mL
over a 0.6% (v/v) agar layer. The agar was then overlaid
with complete DMEM media supplemented with 0.1 μM
puromycin (Life Technology, Paisley, UK). Colonies of
MPNSTs were grown for 14 days at 37°C in 5% CO2.
Media were changed twice a week. Representative pictures
were taken using an inverted AMG EVOS microscope
equipped with an Olympus camera. The diameter of
tumour spheroids was measured using ImageJ software;
the chamber of a haemocytometer (250 μm) was used as a
scale bar for measurement.
Wound healing
Cells were seeded in 60-mm plates and left to reach
100% confluency. Cells were then synchronised in 1%
(v/v) FBS DMEM for 24 h and “wounded” with a pip-
ette tip. Dead cells were removed with PBS wash and
then replaced with DMEM (10% (v/v) FBS). Pictures
were taken at 0 and 12–18 h using an inverted AMG
EVOS microscope equipped with an Olympus camera.
Invasion assays
Transwell permeable supports with 6.5-mm diameter in-
serts, 8.0-μm pore size and a polycarbonate membrane
(Corning, cat no: 3428) were used to perform the in-
vasion assays. Cells were grown in a 75-cm2 flask with
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were then harvested using Trypsin-EDTA. Cells were
counted using a haemocytometer; 1 × 106 cells were re-
suspended in DMEM containing 1% (v/v) FBS. The top
chamber of the Transwell was filled with 300 μl BD
Matrigel basement membrane matrix (1 mg/ml). The
Matrigel was incubated at 37°C for 4 h to allow it to gel.
Cells were then seeded in the upper chamber of the
Transwell; the lower chamber was filled with 600 μl
standard culture medium (10% (v/v) FBS) and 5 mg/mL
fibronectin (R&D systems, Abingdon, UK), as an adhesive
substrate. Cells were incubated at 37°C 5% CO2 for 3 days.
The proportion of adherent cells was then determined by
fixing the cells with methanol and acetone (1:1) for 20
min at −20°C. Cells were then stained with crystal violet
(5 mg/ml) in ethanol for 10 min, followed by a stringent
wash with dH2O until the water ran clear. Crystal violet-
stained cells were eluted with 1% (w/v) SDS and the ab-
sorbance read at 550 nm on a Genova MK3 Life Science
Analyser (Jenway Scientific, Staffordshire, UK). Three
replicates were performed per cell line to enable statis-
tical analysis.Western blotting
The NuPage Novex gel system was used for electropho-
resis as described in the manufacturer’s protocol (Life
Technology, Paisley, UK). Protein samples were resolved
on 4%–12% Bis-Tris gels to identify a band size of 66
kD. Proteins were then transferred to a polyvinylidene
fluoride (PDVF) membrane purchased from Millipore
U.K. Ltd. (Watford, UK), blocked in 5% (w/v) dry milk
powder in standard Tris-buffer saline supplemented with
0.1% (v/v) Tween [as recommended by Cell Signalling
Technology Inc. (Danvers, MA, USA)] for 4 h. Mem-
branes were incubated at 4°C overnight in primary
antibody (1:200 dilutions in 2% (w/v) BSA in TBS-T)
then washed twice for 4 min in TBS-T and incubated
in the appropriate HRP-conjugated secondary antibody
(1:10,000 dilution in 5% (w/v) Marvel in TBS-T) for a
minimum of 30 min at room temperature. Membranes
were washed four times for 3 min with TBS-T and then
incubated in enhanced chemiluminescence (ECL) solu-
tion (GE Healthcare Life Sciences, Buckinghamshire,
UK) for 1 min. Konica Medical Film was used to visu-
alise the signal, and the exposed films were developed
using a Konica Minolta SRX-101A developer.Statistical analysis
SPSS software was used for the statistical analysis of
tumour spheroid formation (n = 40) and the wound
healing (n = 3) and invasion (n = 3) assays. A one-way
ANOVA was performed on the data sets to obtain the
requisite P values.Additional files
Additional file 1: Table S2. The four distinct sets of genes identified
from the various analyses that were performed of differentially
expressed genes.
Additional file 2: Table S3. Data on copy number alterations
compared with the genes found to be differentially expressed between
MPNSTs and PNFs. 76/121 genes exhibited concordance between copy
number changes and the level of expression.
Additional file 3: Figure S1. Results of the q-PCR analysis in relation to
the top 20 genes differentially expressed between MPNSTs and PNFs.
Additional file 4: Table S1. Primers used for q-PCR analysis and results
of the q-PCR analysis.
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